Replies to post #217691 on Biotech Values

[DewDiligence]

RVNC—...the Mylan deal is a net positive if you believe a biosimilar would have entered the market in any event.

Undoubtedly; however, I'm not convinced that any of the companies focusing on FoBs could have accomplished such a feat without RVNC.